Xeris Biopharma (NASDAQ:XERS) Trading Up 5.8% – Still a Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) was up 5.8% on Tuesday . The company traded as high as $8.84 and last traded at $8.8550. 791,879 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 1,892,608 shares. The stock had previously closed at $8.37.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.80.

Xeris Biopharma Trading Down 3.0%

The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The stock’s 50-day moving average is $6.76 and its two-hundred day moving average is $6.66. The company has a market cap of $1.50 billion, a P/E ratio of 144.50 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director John Johnson sold 15,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $91,350.00. Following the completion of the sale, the director owned 683,083 shares in the company, valued at approximately $4,159,975.47. This represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $133,827.98. Following the completion of the transaction, the insider directly owned 1,161,128 shares in the company, valued at approximately $9,323,857.84. This represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 251,500 shares of company stock valued at $1,846,457 over the last ninety days. 4.35% of the stock is owned by insiders.

Institutional Trading of Xeris Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC purchased a new position in shares of Xeris Biopharma during the 4th quarter worth $25,000. KBC Group NV bought a new stake in shares of Xeris Biopharma during the 1st quarter valued at $27,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.